Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria

By Peter Valent, C. Akin, L. Escribano, M. Födinger, K. Hartmann, K. Brockow, M. Castells, W. Sperr, H. Kluin-Nelemans, N. Hamdy and 14 more. European Journal of Clinical Investigation, 2007

745 citations recorded by the source corpus.

Subfields: Immunology, Pharmacology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/592cc96e9f5334329eac51a0dde5be0ce8b4486a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Wallace
2. L. Cox
3. J. Blessing-Moore
4. D. Bernstein
5. D. Dreyfus
6. D. Khan
7. J. Sheikh
8. J. Bernstein

Citations in the corpus

• The diagnosis and management of acute and chronic urticaria: 2014 update. (2014, background): “SM is further classified as indolent systemic mastocytosis, systemic mastocytosis with associated clonal hematologic non–mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia (MCL; leukemic SM variant), extracutaneous mastocytoma, and mast cell sarcoma.(422) Patients with S”